Futura Medical PLC (FUM)

ORD 0.2P

Sell: 4.61p|Buy: 5.88p|Change: 3.58 (-40.60%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Open

4.05p

Previous close

8.83p

Trade high

6.00p

Volume

14,076,209

Year high

40.95p

Year low

4.05p

Dividend yield

–

Market capitalisation

£15.95 mn

P/E ratio

12.79

ISIN

GB0033278473

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 19/09/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Futura Medical PLC	- 40.60
FTSE AIM All Share	+ 0.16
More...

Company profile

Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
19/09/2025	05:05:53	5.245	50,000	2,622.50
19/09/2025	04:24:00	5.76	38,832	2,236.72
19/09/2025	04:23:51	4.6735	4,020	187.87
19/09/2025	04:23:42	4.61	301	13.88
19/09/2025	04:23:22	5.88	1,769	104.02

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.